- Oragenics (NYSE:OGEN) on Thursday said that it had completed the development of its prototype of its automated intranasal device that would help in treating concussed patients.
- The company added that a phase II study is being designed to analyze the effectiveness of ONP-002 on blood biomarkers and patient-reported outcomes of concussed patients.
- The breath-propelled device requires the patient to administer the drug into the nose.
- Press release.
2024-06-27